Family 비비드헬스 함께하는 비만약 이야기,삐약

Bbiyak (삐약), operated under the vvdhealth.com domain, is a South Korean mobile application built specifically for people using GLP-1 receptor agonist obesity treatments such as semaglutide (Wegovy), tirzepatide (Mounjaro) and liraglutide. The app centralizes the routines that these therapies require: logging injection dates and doses, recording body weight and BMI, tracking appetite-control outcomes (meal size, snacks and drinks, alcohol and late-night eating), and noting fasting windows, diet and exercise sessions.

Beyond record-keeping, the product presents analytical and informational views. A weight-loss graph visualizes progress over time, a weight-loss pace check compares a user's rate of loss against literature-based expected rates, and an estimated drug-concentration graph models the amount of medication remaining in the body based on drug half-life, which the company labels a reference estimate that is not a substitute for professional medical advice. Utility features include a directory for finding hospitals and pharmacies that prescribe or dispense the injections, an injection cost calculator that estimates the number of doses and total spend needed to reach a target weight, and a calorie calculator for a target weight-loss zone.

The app also aggregates peer content: an AI feature groups medication reviews from users with similar body profiles (for example, matching height and weight), and a blog and community section provide explanatory material on obesity medications alongside a forum for questions and shared experience. The company positions Bbiyak as the leading domestic diet-injection management app in Korea.

Business model

Consumer mobile application distributed directly to individual users managing GLP-1 obesity treatment, combining self-tracking tools with informational content and a peer community.

Traction

The website displays an aggregate rating of 4.7 out of 5 alongside user reviews, including one from a user reporting roughly nine months of continuous use, and cites active app updates and direct developer-user communication through an open chat channel.